AZD-2014 potentiates resminostat’s cytotoxicity against HCC cells.
AZD-2014 facilitates resminostat-induced HCC cell apoptosis.
AZD-2014 augments resminostat-induced mitochondrial apoptosis pathway activation.
mTOR shRNA or kinase-dead mutation significantly sensitizes HCC cells to resminostat.